ArticleMolecular and cellular biochemistry2026
ALKBH5 promotes gastric cancer angiogenesis by stabilizing LncRNA PVT1 and VEGFA RNAs via m6A demethylation.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expression profiling, molecular subtyping and prognostic signature construction of chemokines and chemokine receptors in gastric cancer.Translational cancer research · 2026Article
- YTHDF proteins differentially regulate a subset of m6A-modified transcripts to restrain endothelial inflammation during homeostasis.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
AlkB homolog 5 (ALKBH5) has been implicated in tumor progression, however, its specific role in angiogenesis in gastric cancer (GC) and the underlying mechanisms remain poorly understood. Messenger RNA (mRNA) expression levels of vascular endothelial growth factor A (VEGFA), ALKBH5, and long non-coding RNA PVT1 (lncRNA PVT1) in GC and paracancerous tissues were measured by quantitative real-time polymerase chain reaction (qRT-PCR). RNA sequencing (RNA-seq) was employed to identify downstream effectors of lncRNA PVT1. The effects of ALKBH5 and lncRNA PVT1 on angiogenesis were examined in vitro and in vivo. The impact of ALKBH5 on the stability of lncRNA PVT1 and VEGFA RNAs was evaluated by mRNA stability assays, and interactions between ALKBH5 and these RNAs were validated using methylated RNA immunoprecipitation (MeRIP) assay. A significant positive correlation was observed among ALKBH5, lncRNA PVT1, and VEGFA expression in both The Cancer Genome Atlas (TCGA) GC database and sixty GC tissue samples. ALKBH5 and lncRNA PVT1 enhanced angiogenesis in AGS and HS746T cells both in vitro and in vivo. RNA-seq revealed that lncRNA PVT1 upregulated VEGFA mainly through the IL17RA/STAT3 signaling pathway. Additionally, ALKBH5 was found to stabilize both lncRNA PVT1 and VEGFA RNAs. MeRIP assays confirmed the direct binding of ALKBH5 to specific sites on lncRNA PVT1 and VEGFA RNAs. In conclusion, ALKBH5 promotes GC angiogenesis primarily through its m6A demethylase activity on targets such as lncRNA PVT1, which regulates VEGFA expression by modulating IL17RA/STAT3 signaling axis. ALKBH5 may serve as a promising biomarker and therapeutic target in GC.
Indexed as
Identifiers
41428170What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.